Synergy pharmaceuticals, inc. (SGYP)
Income statement / TTM
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Net sales

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net sales

-

35,248

25,308

16,820

-

2,412

98

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

15,331

13,131

10,889

8,821

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross profit

26,014

22,117

14,419

7,999

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs and expenses:
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Research and development

11,130

14,102

33,327

48,336

62,752

80,941

84,778

87,056

90,531

86,890

80,509

78,028

82,697

83,219

88,173

83,274

75,173

65,009

49,585

50,630

43,266

39,729

38,300

29,294

25,912

22,550

17,279

13,419

10,011

10,523

0

0

0

Selling, general and administrative

150,426

161,649

179,219

181,862

166,075

135,382

94,151

58,234

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchased in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,004

10,871

11,057

11,581

11,681

11,220

10,371

9,487

7,941

7,716

6,976

6,581

6,746

5,744

6,060

0

0

0

Loss from operations

-135,542

-153,634

-198,127

-222,199

-226,408

-217,190

-180,467

-145,290

-129,839

-114,509

-104,568

-99,822

-100,466

-100,766

-100,605

-94,278

-86,044

-76,066

-61,166

-62,311

-54,486

-51,100

-48,787

-38,235

-34,628

-29,526

-23,860

-20,165

-15,755

-16,584

0

0

0

Other Income (Expense)
Interest expense, net

6,788

4,645

1,785

-548

5,368

5,816

7,144

13,390

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12

0

0

0

-

-

Interest and investment expense, net

-

-

-

-

-

-

-

-

-

-

-

-17,284

-16,326

-12,016

-6,810

-2,464

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt conversion expense

0

0

0

1,209

15,752

15,752

15,752

40,158

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

State R&D tax credits

30

30

30

0

126

126

126

126

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tax credits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

0

-

0

-

0

-

-

-

-

-

Interest and investment income/ (expense), net (includes interest expense of $3,750 on Senior Convertible Debentures for the three months ended March 31, 2015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

218

176

133

105

90

87

94

0

0

0

Change in fair value of derivative financial instruments-warrants

11,939

12,427

9,862

4,340

171

29

-33

105

120

1,653

134

-394

-406

-1,427

871

1,362

920

418

1,465

149

-131

86

-3,034

-1,933

742

4,985

5,604

5,257

3,456

0

0

0

-

Total other expense

-637

1,994

2,289

-2,139

-20,823

-21,413

-22,803

-53,317

-39,347

-40,431

-45,484

-17,678

-17,143

-13,854

-6,267

-1,430

1,040

533

1,514

186

234

500

-2,332

-1,209

1,536

5,736

6,071

5,697

3,532

0

0

0

-

Loss before taxes

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tax expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from Continuing Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Loss from Continuing Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss

-137,312

-151,640

-195,838

-224,338

-247,231

-238,603

-203,270

-198,607

-169,186

-154,940

-150,052

-117,500

-117,609

-114,620

-106,872

-95,708

-85,004

-75,533

-59,652

-62,125

-54,252

-50,600

-51,119

-39,444

-33,092

-23,790

-17,789

-14,468

-12,223

0

0

0

-

Weighted Average Common Shares Outstanding
Basic and Diluted (in shares)

247,994

246,990

246,664

235,924

224,954

224,948

215,484

190,093

179,786

168,127

117,626

113,678

111,328

100,343

96,683

96,190

94,738

94,069

92,056

90,182

90,182

87,482

72,789

66,194

65,806

60,416

54,298

48,657

47,308

46,642

46,167

-

-

Net Loss per Common Share, Basic and Diluted
Net Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Weighted Average Common Shares Outstanding Basic (restated for stock split) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

90,102

88,462

Weighted Average Common Shares Outstanding Diluted (restated for stock split) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

90,102

88,462

Net Loss per Common Share, Basic and Diluted (in dollars per share)

-0.14

-0.12

-0.15

-0.16

-0.22

-0.33

-0.30

-0.31

-0.22

-0.23

-0.51

-0.27

-0.23

-0.34

-0.28

-0.32

-0.24

-0.28

0.18

-0.22

-0.15

-0.11

-0.26

-0.18

-0.15

-0.17

-0.13

-0.12

-0.01

-0.10

-0.08

-0.04

-0.07